Skip to main content

BioTechniques is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Journal
    • Aims and scope
    • Journal archive
    • Editorial board
    • For authors
    • Your editors: what do we do?

    Follow us on social media

  • Current issue
  • News
    • Latest news
    • Tech news
    • Events news
    • Company news

    Follow us on social media

  • Multimedia
    • Downloadable eBooks
    • Infographics
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • Features
    • Interviews
    • Opinion
    • In Focus
    • Spotlights
    • Companies
    • New products
    • Events

    Follow us on social media

  • Topics
    • Analytical chemistry
      • Biochemistry
      • Bioengineering and biophysics
      • Cancer research
      • Careers and Publishing
      • Cell and tissue biology
      • COVID-19
      • CRISPR
      • Computational biology
    • Diagnostics and preclinical
      • Drug discovery and development
      • Imaging
      • Immunology
      • Lab design and machinery
      • Microbiology
      • Molecular biology
    • Nanomedicine
      • Neuroscience
      • PCR and sequencing
      • Plant and climate science
      • Proteomics
      • Veterinary science
      • Whole-genome studies

    Follow us on social media

  • Become a member
Webinar | Multiplex imaging and spatial analysis for biomarker-driven TME profiling 2 days 16 hours 39 mins 13 secs Sign up now!

Reversing Alzheimer’s symptoms in mice with axitinib treatment

8 Oct 2021
Written by Ryan Gilroy (Commissioning Editor)
Drug discovery and development Neuroscience News

Alzheimer's and chemotherapy

Axitinib restored memory and cognitive function in mice that display symptoms of Alzheimer’s disease.

University of British Columbia (Canada) researchers demonstrated restoration of both memory and cognitive function in mice that display symptoms of Alzheimer’s disease by treatment with axitinib, a common chemotherapy drug.

READ MORE ON NEURO CENTRAL NOW

Top content

  • Hunting zombie cells: novel technique for tagging senescent cells
  • Leptin neural circuit restores balance after anxiety upsets it
  • Blood factor reverses aging in hematopoietic stem cells

Related tags

Alzheimer's Disease chemotherapy
Previous article Next article

Related articles

23 JAN 2020 NEUROSCIENCE

Tau beats amyloid in top spot for predicting Alzheimer’s-associated neurodegeneration

13 JAN 2022 NEUROSCIENCE

Jogging your memory: it’s more literal than you’d think

29 JUL 2024 NEUROSCIENCE

Novel microscopy technique provides insights into amyloid architecture

BioTechniques journal logo feature image
17 AUG 2021 MOLECULAR BIOLOGY

How credible is your scientific research? Find out in your latest issue of BioTechniques

Chaperone-mediated autophagy in Alzheimer's disease novel drug neuron
28 APR 2021 NEUROSCIENCE

Taking out the trash: the journey of an extraordinary, experimental Alzheimer’s drug

23 NOV 2021 NEUROSCIENCE

Got lost doing the shopping? Why it happens and how your brain tries to avoid it

  • About BioTechniques
  • Advisory Board
  • Contact Us
  • Advertising
  • Permissions
  • Whitelist Emails
  • Press release policy
  • Accessibility
Contact
Contact Us
Office info

BioTechniques is powered by Taylor & Francis Group

BioTechniques, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom

Impact Factor 2.2 | CiteScore 2.0

  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2025 BioTechniques